Reply to Dee, and Johnson and Folayan

Affiliations

Comment

Jean-Daniel Lelièvre. J Infect Dis. 2019.

. 2019 Aug 30;220(7):1234.

doi: 10.1093/infdis/jiz265.

¹ Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Henri Mondor, Creteil, France.

No abstract available

Comment on

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.
Lelièvre JD, Hocqueloux L. Lelièvre JD, et al. J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S5-S6. doi: 10.1093/infdis/jiz012. J Infect Dis. 2019. PMID: 30779842 Free PMC article.
Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
Lelièvre JD. Lelièvre JD. J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S16-S18. doi: 10.1093/infdis/jiz036. J Infect Dis. 2019. PMID: 30860581 Free PMC article.
Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions.
Dee L, Boone CA, Palm D, Campbell D, Dubé K. Dee L, et al. J Infect Dis. 2019 Aug 30;220(7):1230-1231. doi: 10.1093/infdis/jiz262. J Infect Dis. 2019. PMID: 31505661 Free PMC article. No abstract available.
Re: Pre-Exposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
Folayan MO, Haire B, Noseda V. Folayan MO, et al. J Infect Dis. 2019 Aug 30;220(7):1231-1233. doi: 10.1093/infdis/jiz263. J Infect Dis. 2019. PMID: 31505662 No abstract available.
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.
Johnson T, Folayan MO. Johnson T, et al. J Infect Dis. 2019 Aug 30;220(7):1233-1234. doi: 10.1093/infdis/jiz264. J Infect Dis. 2019. PMID: 31505663 No abstract available.